Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.

Sanofi, Formation Bio and OpenAI have joined forces to build ... “At scale, this AI-driven development approach can ...

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Please find enclosed a copy of the Postal Ballot Notice together with the Explanatory Statement for your record. We have also enclosed the Calendar of Events for the Postal Ballot process for your ...

However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

In October 2023, Sanofi announced plans to separate its consumer health unit in 2024. Sanofi’s consumer health division, with ...

Sanofi (NASDAQ:SNY – Free Report) by 30.4% during the third quarter, according to the company in its most recent filing with ...

Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and Dulcolax.

Sanofi has entered exclusive negotiations to sell a 50% controlling stake in its consumer health business, Opella, to the US private equity firm Clayton, Dubilier & Rice (CD&R). Opella ...